No black box warning on record for Recarbrio
As of the latest FDA labeling reviewed, Recarbrio (IMIPENEM ANHYDROUS, CILASTATIN, AND RELEBACTAM ANHYDROUS) does not carry a black box warning. Standard warnings and precautions still apply — see the full Recarbrio medicine page for the complete safety profile.